Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae

Chemotherapy

Volumn 46, Issue 5, 2000, Pages 303-308

  Kim, Baek Nam ^a,b   Woo, Jun Hee ^a   Kim, Yang Su ^a   Ryu, Jiso ^a   Kim, Mi Na ^a   Pai, Chik Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

Carbapenems; Cephalosporins; Drug interactions; Meningitis; Streptococcus pneumoniae; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; MEROPENEM; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0033808045     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007302     Document Type: Article

References (31)

1. Appelbaum PC: Antimicrobial resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis 1992;15:77-83.
2. Bradley JS, Connor JD: Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991;10:871-873.
3. Friedland IR, Shelton S, Paris M, Rinderknecht S, Ehrett S, Krisher K, McCracken GH Jr: Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1993;12:196-200.
4. Friedland IR, McCracken GH Jr: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377-382.
5. Lee HJ, Park JY, Jang SH, Kim JH, Kim EC, Choi KW: High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clin Infect Dis 1995;20:826-835.
6. Song JH, Yang JW, Peck KR, Kim S, Lee MY, Jacobs MR, Appelbaum PC, Pai CH: Spread of multidrug-resistant Streptococcus pneumoniae in South Korea. Clin Infect Dis 1997;25:747-749.
7. Choi EH, Lee HJ: Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-1354.
8. Viladrich PF, Gudiol F, Linares J, Pallares R, Sabate I, Rufi G, Ariza J: Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991;35:2467-2472.
9. Friedland IR, Paris M, Shelton S, McCracken GH: Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J Antimicrob Chemother 1994;34:231-237.
10. Friedland IR, Paris M, Ehrett S, Hickey S, Olsen K, McCracken GH Jr: Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1993; 37:1630-1636.
11. Paris MM, Ramilo O, McCracken GH Jr: Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995;39:2171-2175.
12. Bradley JS, Scheld WM: The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: Current antibiotic therapy in the 1990s. Clin Infect Dis 1997;24(suppl 2): S213-S221.
13. Quagliarello VJ, Scheld WM: Treatment of bacterial meningitis. N Engl J Med 1997;336:708-716.
14. Spangler SK, Jacobs MR, Appelbaum PC: Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994; 38:898-900.
15. Fitoussi F, Doit C, Benali K, Bonacorsi S, Geslin P, Bingen E: Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother 1998;42:942-944.
16. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS: Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-125.
17. Doit CP, Bonacorsi SP, Fremaux AJ, Sissia G, Cohen R, Geslin PL, Bingen EH: In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother 1994; 38:2655-2659.
18. Barakett V, Lesage D, Delisle F, Richard G, Petit JC: Killing kinetics of imipenem against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 1994;33: 1025-1028.
19. Dagan RL, Velghe L, Rodda JL, Klugman KP: Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994;34: 175-179.
20. Narin K, Shepherd GL, Edwards JR: Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 1995;36(suppl A):S73-S84.
21. Barakett V, Lesage D, Delisle F, Richard G, Petit JC: Killing kinetics of meropenem against penicillin-resistant pneumococci. J Antimicrob Chemother 1996;38:1085-1089.
22. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 4; Approved Standard. NCCLS document M7-A4. Wayne, NCCLS, 1997.
23. Trang JM, Jacobs RF, Kearns GL, Brown AL, Wells TG, Underwood FL, Kluza RB: Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrob Agents Chemother 1985;28:791-795.
24. Klugman KP, Friedland IR, Bradley JS: Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995;39:1988-1992.
25. Eliopoulos GM, Moellering RC Jr: Antimicrobial combinations; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 3. Baltimore, Williams & Wilkins, 1991, pp 432-492.
26. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. NCCLS document M100-S8. Wayne, NCCLS, 1998.
27. Bingen E, Lambert-Zechovsky N, Mariani-Kurkdjian P, Doit C, Aujard Y, Fournerie F, Mathieu H: Bacterial counts in cerebrospinal fluid of children with meningitis. Eur J Clin Microbiol Infect Dis 1990;9:278-281.
28. Fuchs PC, Barry AL, Brown SD: Pneumococcal susceptibility to meropenem. J Antimicrob Chemother 1996;37:1036-1037.
29. Klugman KP, Dagan R: Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995;39: 1140-1146.
30. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A: A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. J Antimicrob Chemother 1995;36(suppl A):S85-S97.
31. Kaplan SL, Mason EO Jr: Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998;11:628-644.